JERSEY CITY, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drugresistant infections, today announced David Angulo, M.D., President and Chief Executive Officer, will make a corporate presentation as well as host 1x1 meetings at the H. C. Wainwright 26th Annual Global Investment Conference on Wednesday, September 11 at 10:00 A.M. ET. H. C. Wainwright 26th Annual Global Investment Con ...

Clinical study reports for the FURI, CARES and NATURE trials in refractory or resistant invasive fungal infections were delivered to GSK, triggering a $10 million development milestone payment to SCYNEXIS which we expect to receive in Q3 2024. SCY-247's IND-enabling activities continue to progress. Pre-clinical in vitro and in vivo studies, presented at several medical conferences, have shown potent and broad antifungal activity. Phase 1 study initiation is planned for Q4 2024. SCYNEXIS ended Q2 2024 with c ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to | --- | --- | |---------------------------------------------------------------------------------------------------------------------------|---------------------- ...

JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drugresistant infections, today announced that it will receive a $10 million development milestone payment under its exclusive license agreement with GSK for ibrexafungerp. The milestone payment is triggered by the delivery of final clinical study reports for the completed FURI, CARES, and NATURE clinical studies. "We are p ...

Results from the open-label studies of ibrexafungerp in patients with refractory or resistant fungal diseases (FURI) and in patients with Candidiasis caused by Candida auris (CARES) are positive and consistent with previously announced interim analyses and are expected to be presented at a future scientific meeting. NATURE was an observational study to evaluate the outcome of patients with invasive candidiasis treated with available standard of care options and was designed as an external control strategy f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR Delaware 56-2181648 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) Delaware 56-2181648 (State or other jurisdiction of incor ...

Revenue Performance - License agreement revenue for the full year 2023 was $139 million, a significant increase from $103 thousand in 2022[8] - Net product revenue from BREXAFEMME was $1.0 million in 2023, down from $5.0 million in 2022[8] - Total revenue for 2023 reached $140.1 million, compared to $5.1 million in 2022[20] Expenses - Research and development expenses increased by 14% to $30.9 million in 2023, up from $27.3 million in 2022[10] - Selling, general and administrative expenses decreased by 67% to $20.9 million in 2023, down from $63.0 million in 2022[11] Cash and Investments - SCYNEXIS ended 2023 with cash, cash equivalents, and investments totaling $98.0 million, compared to $73.5 million at the end of 2022[14] - The company projects a cash runway of more than two years based on its current operating plan[14] Clinical Development - SCY-247 is expected to initiate Phase I clinical studies in the second half of 2024[4] - A $10 million development milestone payment is anticipated upon delivery of clinical study reports to GSK in the first half of 2024[5] Net Income and Loss - Net income for 2023 was $67.0 million, or $1.40 per share, compared to a net loss of $62.8 million, or $1.47 per share in 2022[13] Assets and Liabilities - Total assets increased to $128,412 million as of December 31, 2023, up from $87,810 million in 2022, representing a growth of 46%[23] - Current assets rose to $102,116 million, compared to $79,061 million in the previous year, marking a 29% increase[23] - Total liabilities decreased to $55,450 million from $84,577 million, a reduction of 34%[23] - Stockholders' equity significantly improved to $72,962 million, up from $3,233 million, reflecting a growth of 2,158%[23] Cash Flow and Deficits - Cash and cash equivalents decreased to $34,050 million from $45,814 million, a decline of 26%[23] - Accounts payable increased to $7,149 million, up from $5,937 million, indicating a rise of 20%[23] - Accumulated deficit improved to $(355,247) million from $(422,288) million, a reduction of 16%[23] - Additional paid-in capital slightly increased to $428,169 million from $425,485 million, a growth of 1.0%[23] - Total current liabilities decreased to $16,303 million from $17,618 million, a decline of 7%[23] - Warrant liabilities increased to $21,680 million from $18,644 million, reflecting a rise of 11%[23]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acce ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period to Commission File Number 001-36365 SCYNEXIS, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organizat ...